Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 9 February 2018

Summit Therapeutics to Participate in Upcoming Investor Conferences

     

Published: 13:00 CET 09-02-2018 /GlobeNewswire /Source: Summit Therapeutics plc / : SUMM /ISIN: GB00BN40HZ01

Summit Therapeutics to Participate in Upcoming Investor Conferences

Summit Therapeutics plc

("Summit", or the "Company")

SUMMIT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Oxford, UK, 9 February 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that management will participate in two upcoming investor conferences in New York City, US.

  • BIO CEO & Investor Conference - 12 February 2018, presentation at 3:15pm EST
  • SunTrust Robinson Humphrey 4th Annual Orphan Drug Day - 13 February 2018

A live audio webcast of the BIO CEO presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. For the SunTrust Robinson Humphrey Orphan Drug Day, the Company will participate in one on one meetings.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

 

 

Summit

 

 

Glyn Edwards / Richard Pye (UK office)

Tel:

44 (0)1235 443 951

Erik Ostrowski / Michelle Avery (US office)

 

+1 617 225 4455

 

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Tel:

+44 (0)20 7213 0880

Liam Murray / Tony Rawlinson

 

 

 

 

 

N+1 Singer (Joint Broker)

Tel:

+44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

 

 

 

 

 

Panmure Gordon (Joint Broker)

Tel:

+44 (0)20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

 

 

Tom Salvesen, Corporate Broking

 

 

 

 

 

MacDougall Biomedical Communications (US)

Tel:

+1 781 235 3060

Karen Sharma

 

ksharma@macbiocom.com

 

 

 

Consilium Strategic Communications (UK)

Tel:

+44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart /

 

summit@consilium-comms.com

Jessica Hodgson / Philippa Gardner

 

 

 

-END-





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Summit Therapeutics plc, 85b Park Drive Milton Park, Abingdon OX14 4RY,, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.